| Aug 14 |
Iterum Therapeutics GAAP EPS of -$0.30 beats by $0.15
|
| Aug 14 |
Iterum Therapeutics Reports Second Quarter 2024 Financial Results
|
| Aug 13 |
Iterum Therapeutics Q2 2024 Earnings Preview
|
| Aug 7 |
Iterum Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
|
| Aug 6 |
Iterum Therapeutics Announces Expiration and Results of Rights Offering
|
| Aug 2 |
Iterum Therapeutics Broadens Patent Estate for Oral Sulopenem
|
| Jul 22 |
Iterum Therapeutics Starts Rights Offering
|
| Jul 22 |
Iterum Therapeutics Commences Rights Offering
|
| Jun 21 |
Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections
|
| Jun 5 |
Iterum Therapeutics to Present Data at ASM Microbe 2024
|
